secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenwich LifeSciences, Inc. (GLSI)
CIK:        0001799788
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001493152-23-012053
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Greenwich LifeSciences confirms FDA review of Phase IIb data, provides Flamingo-01 trial update
--------------------------------------------------------------------------------

- FDA reviewed Phase IIb clinical data before Flamingo-01 Phase III trial commencement.
- First US sites activated in Q3 2022; patient enrollment and treatment ongoing since Q4 2022.
- DTH skin tests and blood samples collected to assess immune response.
- Company planning expansion of Flamingo-01 clinical trial into Europe.
- Abstract and poster on Flamingo-01 design presented at AACR on April 17, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799788/000149315223012053/0001493152-23-012053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799788/000149315223012053/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer